Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1 1

Status

Completed 180Recruiting 72Unknown 38Terminated 36Active not recruiting 27Not yet recruiting 11Withdrawn 6Suspended 2Available 2Enrolling by invitation 1Approved for marketing 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 10Gastrointestinal 2Thoracic 1Gynecologic 1Breast 1

Conditions

Colorectal Neoplasms 28Pancreatic Neoplasms 17Stomach Neoplasms 13Carcinoma, Hepatocellular 13Breast Neoplasms 9Rectal Neoplasms 7Neoplasms 7Esophageal Neoplasms 7Colonic Neoplasms 7Prostatic Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Ovarian Neoplasms 3Neoplasm Metastasis 3Lung Neoplasms 3Endometrial Neoplasms 3Diabetes Mellitus 3Crohn Disease 3Cholangiocarcinoma 3Carcinoma, Renal Cell 3Bile Duct Neoplasms 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Sarcoma 2Peritoneal Neoplasms 2Multiple Sclerosis 2Multiple Myeloma 2Melanoma 2Liver Neoplasms 2Irritable Bowel Syndrome 2Head and Neck Neoplasms 2

Interventions

palbociclib 1gedatolisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Suspended × Head and Neck Neoplasms × Gastrointestinal × Clear all
NCT04541381 2026-05-07

The PhOCus Trial: Implementation of Pharmacogenomic Testing in Oncology Care

University of Chicago

Phase NA Suspended
860 enrolled
BreastGastrointestinalHead & Neck

Breast Neoplasms, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Dihydropyrimidine Dehydrogenase Deficiency

NCT03065062 2026-02-13

Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors

Dana-Farber Cancer Institute

Phase 1 Suspended
75 enrolled
GastrointestinalGynecologicHead & Neck

Head and Neck Neoplasms, Neoplasms, Pancreatic Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡